Studying the Treatment Effect of Pirfenidone in Chronic Lung Allograft Dysfunction (STOP-CLAD)
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
Greater than 50% of lung transplant recipients show signs of chronic lung allograft
dysfunction (CLAD) by 5 years post-transplantation.Therapies to prevent or slow CLAD are
lacking. Anti-fibrotic therapies may offer an avenue to prevent progression of CLAD and
prolong allograft survival. This study investigates if Pirfenidone therapy will stabilize
lung function decline and slow progression of Functional small airways disease (fSAD) in lung
transplant recipients with CLAD.